{"nctId":"NCT04599465","briefTitle":"A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)","startDateStruct":{"date":"2021-01-15","type":"ACTUAL"},"conditions":["Cystic Fibrosis"],"count":69,"armGroups":[{"label":"ELX/TEZ/IVA","type":"EXPERIMENTAL","interventionNames":["Drug: ELX/TEZ/IVA","Drug: IVA"]}],"interventions":[{"name":"ELX/TEZ/IVA","otherNames":["VX-445/VX-661/VX-770","elexacaftor/tezacaftor/ivacaftor"]},{"name":"IVA","otherNames":["VX-770","ivacaftor"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Heterozygous for F508del and an MF mutation (F/MF genotypes)\n* Forced expiratory volume in 1 second (FEV1) value ≥ 30% of predicted mean for age, sex, and height\n* Abnormal glucose tolerance determined by an OGTT as either:\n\n  * Impaired glucose tolerance (IGT) defined as 2 hour post OGTT blood glucose level ≥140 to \\<200 mg/dL (≥7.77 to \\<11.10 mmol/L) and fasting blood glucose level \\<126 mg/dL (\\<7.00 mmol/L)\n  * CF-related diabetes (CFRD) defined as either fasting hyperglycemia (blood glucose level ≥126 mg/dL \\[≥7.00 mmol/L\\] after an 8-hour fast) or 2-hour post OGTT blood glucose level ≥200 mg/dL (≥11.10 mmol/L)\n\nKey Exclusion Criteria:\n\n* Clinically significant liver cirrhosis with or without portal hypertension\n* Solid organ or hematological transplantation\n* Lung infection with organisms associated with a more rapid decline in pulmonary status\n* Type 1 or Type 2 diabetes\n* Duration of CFRD ≥5 years\n\nOther protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in 2-hour Blood Glucose Levels Following an OGTT to the Average of Week 36 and Week 48","description":"Baseline 2-hour post-OGTT blood glucose level was defined as the average of valid pre-dose measurements at screening and Day 1. OGTT results were considered valid only when the participant was fasting for at least 8 hours.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Improvement in Dysglycemia Categorization at Week 48","description":"Baseline dysglycemia category was defined as the most recent non-missing measurement before the first dose of study drug in the treatment period. Improvement in dysglycemia is a change from cystic fibrosis-related diabetes (CFRD) at baseline to impaired glucose tolerance (IGT)/normal glucose tolerance (NGT) at Week 48 OR change from IGT at baseline to NGT at Week 48. CFRD: 2-hour post-OGTT blood glucose level ≥200 mg/dL or fasting blood glucose level ≥126 mg/dL; IGT: 2-hour post-OGTT blood glucose level ≥140 to \\<200 mg/dL and fasting blood glucose level \\<126 mg/dL; NGT: 2 hour post-OGTT blood glucose level \\<140 mg/dL and fasting blood glucose level \\<126 mg/dL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":69},"commonTop":["COVID-19","Pyrexia","Headache","Nasopharyngitis","Diarrhoea"]}}}